Compare Ginkgo Bioworks Holdings Inc (DNA) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Select Medical Holdings Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.96 (market cap $590.53M), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Select Medical Holdings Corporation is far larger — about 3.5× Ginkgo Bioworks Holdings Inc's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | SEM | |
|---|---|---|
Market Cap | $590.53M | $2.05B |
Sector | Health | Health |
52-Week High | $16.14 | $16.66 |
52-Week Low | $5.48 | $11.77 |
Enterprise Value | $627.78M | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Select Medical Holdings (SEM) trades at $16.51, unchanged on the day, following its recent acquisition completion by a consortium led by Robert A. Ortenzio and Martin F. announced on June 30, 2026. The stock shows mixed signals with a bullish overall technical outlook but bearish moving averages, while fundamentals indicate modest profitability with a net income margin of 2.42% and a P/E ratio of 15.43. Recent earnings have been inconsistent, with Q1 2026 missing expectations.
The acquisition at $16.50 per share caps near-term upside, with legal investigations into board fiduciary duties posing reputational risks. Analyst sentiment is neutral with a 57.15% hold rating, reflecting uncertainty post-buyout. Investors face limited growth prospects amid stable revenues and margin pressures, emphasizing caution in the current holding pattern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
